share_log

公告精选 | 比亚迪3月汽车销量30.25万辆,同比增长46.06%;中远海能去年盈利涨逾一倍

Featured announcements | BYD sold 302,500 vehicles in March, up 46.06% year on year; COSCO Haineng's profit more than doubled last year

cls.cn ·  Apr 2 08:06

① BYD Co., Ltd. sold 302,500 new energy vehicles in March, up 46.06% year on year; ② COSCO Haineng's profit more than doubled last year. How big is the profit scale?

Recent important announcements for Hong Kong stocks are as follows:

Operational data

$BYD COMPANY (01211.HK)$In March, sales of new energy vehicles were 302,500 units, up 46.06% year on year.

$LI AUTO-W (02015.HK)$In March, 28,984 new vehicles were delivered, an increase of 39.2% over the previous year.

$NIO-SW (09866.HK)$In March, 11,866 vehicles were delivered, up 14.3% year over year.

$XPENG-W (09868.HK)$In March, 9,026 new vehicles were delivered, up 99% month-on-month and 29% year-on-year.

$GWMOTOR (02333.HK)$Sales in March were 100,276 units, up 11.02% year over year.

Results Express

$CHINA RAIL CONS (01186.HK)$: In 2023, revenue was 1137.993 billion yuan, up 3.8% year on year; net profit was 26.097 billion yuan, down 2.19% year on year.

In 2023, the Group signed a total of 3293.87 billion yuan of new contracts, an increase of 1.51% over the previous year. As of December 31, 2023, the total amount of unfinished contracts of the Group was 668.89,825.3 billion yuan, an increase of 5.14% over the previous year.

$BANK OF CHINA (03988.HK)$: 2023 revenue of 624.138 billion yuan, up 6.42% year on year; net profit of 231.904 billion yuan, up 2.38% year on year.

$PSBC (01658.HK)$: 2023 revenue of 342,912 billion yuan, up 0.24% year on year; net profit of 86.27 billion yuan, up 1.23% year on year.

$GWMOTOR (02333.HK)$: Total revenue in 2023 was approximately RMB 173.212 billion, up 26.12% year on year; net profit was about RMB 7.022 billion, down 15.06% year on year.

$CHINA RES GAS (01193.HK)$: Revenue of HK$101,272 billion in 2023, up 7.35% year on year; net profit of HK$5.223 billion, up 10.36% year on year. The Group's overall gross margin was 18.2%, down 1 percentage point from the same period last year.

$ZHONGLIANG HLDG (02772.HK)$: Revenue in 2023 was about 66.62 billion yuan, an increase of about 69.4% year-on-year; net loss was 4.25 billion yuan, an increase of 215.3% over the previous year.

$ZOOMLION (01157.HK)$: 2023 revenue of 47.075 billion yuan, up 13.08% year on year; net profit of 3.55 billion yuan, up 51.26% year on year.

$COSCO SHIP ENGY (01138.HK)$: 2023 revenue of 21.912 billion yuan, up 18.02% year on year; net profit of 3.349 billion yuan, up 129.23% year on year.

In 2023, the transportation volume was 172.593 million tons, a year-on-year decrease of 1.0%; the transportation turnover (excluding term leases) was 530.49 billion tonnes, a decrease of 1.2% year-on-year;

$JOY CITY PPT (00207.HK)$: 2023 revenue of 13.272 billion yuan, a year-on-year decrease of 36.3%; net profit of 340 million yuan, a year-on-year decrease of 35.94%.

$BEIGENE (06160.HK)$: Total revenue for 2023 was US$2,459 million, up 73.65% year over year. For the year ended December 31, 2023, Baiyuze's global sales totaled US$1.3 billion, an increase of 128.5% over the previous year.

$FENBI (02469.HK)$: In 2023, we achieved revenue of 3.02 billion yuan, gross profit of 1.57 billion yuan, an increase of 14.9% year on year; adjusted net profit of 450 million yuan, an increase of 134.1% year on year.

$SINO BIOPHARM (01177.HK)$: In 2023, continuous operating revenue was RMB 26.199 billion, up 0.67% year on year; net profit was RMB 2,332 billion, down 8.32% year on year.

$HEC CJ PHARM (01558.HK)$: In 2023, revenue was 6.295 billion yuan, up 68.08% year on year, and net profit was 1,993 billion yuan, up 2501.23% year on year.

Sales of the core product Kewei (oseltamivir phosphate capsules and granules) were 5.509.5 billion yuan, an increase of 78.15% over the same period last year.

$CHENMING PAPER (01812.HK)$: 2023 revenue of 26.609 billion yuan, a year-on-year decrease of 16.86%; net loss of 1,281 billion yuan.

$SHIMAO SERVICES (00873.HK)$: In 2023, revenue was 8.203 billion yuan, and net profit was 273 million yuan, turning a year-on-year loss into a profit.

$SHANDONG XINHUA (00719.HK)$: Revenue in 2023 was about 8.1 billion yuan, up 7.97% year on year; net profit was about 496.5 million yuan, up 20.79% year on year.

$TIGERMED (03347.HK)$: 2023 revenue of 7.384 billion yuan, up 4.2% year on year; net profit of 2,026.5 billion yuan, up 0.5% year on year.

$ASYMCHEM (06821.HK)$: Revenue of 2023 was about 7.781 billion yuan, a year-on-year decrease of 23.94%; net profit of 2,269 billion yuan, a year-on-year decrease of 31.28%. Excluding orders for which revenue has been confirmed during the reporting period, the company still has $874 million in on-hand orders.

$KEEP (03650.HK)$: Revenue of $2,138 billion in 2023, a year-on-year decrease of 3.3%; net profit of $1,106 billion, loss of $105.5 million.

Buyback News

$TENCENT (00700.HK)$: On March 28, HK$1.03 billion was spent to repurchase 3.28 million shares at a repurchase price of HK$301.8-308.6.

$XIAOMI-W (01810.HK)$: On March 28, HK$52.4332 million was spent to repurchase 350,000 shares at a repurchase price of HK$14.94-15.00.

$CK ASSET (01113.HK)$: On March 28, HK$120 million was spent to repurchase 3.719 million shares at a repurchase price of HK$32.05-32.3.

$HSBC HOLDINGS (00005.HK)$: Approximately HK$273 million was spent to repurchase 4.448,800 shares at a repurchase price of HK$61.25-HK$61.75.

$AIA (01299.HK)$: Spend HK$28.554,500 to repurchase 550,000 shares at a repurchase price of HK$50.2-52.95.

$GUSHENGTANG (02273.HK)$: Spend HK$21.835,800 to repurchase 49,400 shares at a repurchase price of HK$43.2-44.1.

edit/new

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment